Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-11
2011-01-11
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S374000, C544S391000, C546S207000, C546S226000, C514S330000
Reexamination Certificate
active
07868009
ABSTRACT:
The present invention is related to N-hydroxyamide derivatives of Formula (I):and use thereof in particular for the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis.
REFERENCES:
patent: 5540938 (1996-07-01), Masterson et al.
patent: 0 627 406 (1994-12-01), None
patent: WO 95/33731 (1995-12-01), None
patent: WO 98/48802 (1998-11-01), None
patent: WO 99/55678 (1999-11-01), None
patent: WO 99/67230 (1999-12-01), None
patent: WO 01/45698 (2001-06-01), None
patent: WO 01/47920 (2001-07-01), None
patent: WO 01/83461 (2001-11-01), None
patent: WO 02/28866 (2002-04-01), None
patent: WO 02/080897 (2002-10-01), None
patent: WO 03/068230 (2003-08-01), None
patent: WO 03/070711 (2003-08-01), None
patent: WO 03/084941 (2003-10-01), None
patent: WO 2004/028521 (2004-04-01), None
patent: WO 2004/043965 (2004-05-01), None
patent: 2006/010751 (2006-02-01), None
Birkedal-Hansen et al. Critical Reviews in Oral Biology and Medicine, vol. 4(2), p. 197-250 (1993).
Vincenti et al. Arthritis & Rheumatism vol. 17, p. 1115-1126 (1994).
Matrx Metalloproteinase, from Wikipedia,the free encyclopedia (8 pages), retrieved from the Internet on Dec. 17, 2009 at http://en.wikipedia.org/wiki/Matrix—metalloproteinase.
Muroski et al. Curr.Pharm.Biotechnol. 9(1),p. 34-46 (2008).
Belvisi, M., et al., “Review: The Role of Matrix Metalloproteinases (MMPs) in the Pathophysiology of Chronic Obstructive Pulmonary Disease (COPD): A Therapeutic Role for Inhibitors of MMPs?,”Inflammation Research, 52: 95-100 (2003).
Clark, I., et al., “Metalloproteinases: Their Role in Arthritis and Potential as Therapeutic Targets,”Expert Opin. Ther. Targets, 7(1): 19-34 (2003).
Doherty, T., et al., “Therapeutic Developments in Matrix Metalloproteinase Inhibition,”Expert Opin. Ther. Patents, 12(5): 665-707 (2002).
Fingleton, B., “Matrix Metalloproteinase Inhibitors for Cancer Therapy: the Current Situation and Future Prospects,”Expert Opin. Ther. Targets, 7(3): 385-397 (2003).
Galis, Z., et al., “Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: The Good, the Bad, and the Ugly,”Circulation Research, 90: 251-262 (2002).
Henrotin, Y., et al., “The Inhibition of Metalloproteinases to Treat Osteoarthritis: Reality and New Perspectives,”Expert Opin. Ther. Patents, 12(1): 29-43 (2002).
Hooper, N., et al., “Membrane Protein Secretases,”Biochem. J., 321: 265-279 (1997).
Horstmann, S., et al., “Profiles of Matrix Metalloproteinases, Their Inhibitors, and Laminin in Stroke Patients,”Stroke, 34(9): 2165-2172 (2003).
Ingman, T., et al., “Matrix Metalloproteinases and Their Inhibitors in Gingival Crevicular Fluid and Saliva of Periodontitis Patients,”Journal of Clinical Periodontology, 23: 1127-1132 (1996).
Knight, C., et al., “A Novel Coumarin-labelled Peptide for Sensitive Continuous Assays of the Matrix Metalloproteinases,”Federation of European Biochemical Societies Letters, 296(3): 263-266 (1992).
Krishna, G., et al., “New Therapies for Chronic Obstructive Pulmonary Disease,”Expert Opin. Investig. Drugs, 13(3): 255-267 (2004).
Leppert, D., et al., “Matrix Metalloproteinases: Multifunctional Effectors of Inflammation in Multiple Sclerosis and Bacterial Meningitis,”Brain Research Reviews, 36: 249-257 (2001).
Liu, M., et al., “Association of Increased Expression of Macrophage Elastase (Matrix Metalloproteinase 12) With Rheumatoid Arthritis,”Arthritis&Rheumatism, 50(10): 3112-3117 (2004).
Makrakis, E., et al., “Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 in Plasma/serum and Urine of Women During Term and Threatened Preterm Labor: A Clinical Approach,”The Journal of Maternal-Fetal and Neonatal Medicine, 14(3): 170-176 (2003).
Opdenakker, G., et al., “Functional Roles and Therapeutic Targeting of Gelatinase B and Chemokines in Multiple Sclerosis,”The Lancet Neurology, 2: 747-756 (2003).
Peterson, J., “Matrix Metalloproteinase Inhibitor Development and the Remodeling of Drug Discovery,”Heart Failure Reviews, 9: 63-79 (2004).
Skiles, J., et al., “The Design, Structure, and Therapeutic Application of Matrix Metalloproteinase Inhibitors,”Current Medicinal Chemistry, 8(4): 425-474 (2001).
Skotnicki, J., et al., “Design Strategies for the Identification of MMP-13 and TACE Inhibitors,”Current Opinion in Drug Discovery&Development, 6(5): 742-759 (2003).
Visse, R., et al., “Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases: Structure, Function, and Biochemistry,”Circulation Research, 92: 827-839 (2003).
Vos, C., et al., “Matrix Metalloproteinase-12 is Expressed in Phagocytotic Macrophages in Active Multiple Sclerosis Lesions,”Journal of Neuroimmunology, 138: 106-114 (2003).
Wada, C., et al., “Phenoxyphenyl SulfoneN-Formylhydroxylamines (Retrohydroxamates) as Potent, Selective, Orally Bioavailable Matrix Metalloproteinase Inhibitors,”J. Med. Chem., 45(1): 219-232 (2002).
International Search Report for International Application No. PCT/EP2006/050480 dated Apr. 21, 2006.
Written Opinion of the International Searching Authority, International Application No. PCT/EP2006/050480 dated Apr. 21, 2006.
Notification Concerning Transmittal of International Preliminary Report on Patentability, and International Preliminary Report on Patentability, International Application No, PCT/EP2006/050480 dated Jul. 31, 2007.
Gonzalez Jerome
Swinnen Dominique
Bernhardt Emily
Hamilton Brook Smith & Reynolds P.C.
Merck Serono S.A.
LandOfFree
N-hydroxyamide derivatives and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-hydroxyamide derivatives and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-hydroxyamide derivatives and use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2657763